Inverse Agonists and Basal (Constitutive) Activity

Some receptors are active to a degree even without any ligand bound — they have basal, or constitutive, activity. An inverse agonist is a ligand that binds such a receptor and reduces this baseline activity below its unliganded level, in contrast to a neutral antagonist, which binds without changing basal activity. Inverse agonism is therefore described as negative efficacy, and it is detectable only in systems where the receptor has measurable constitutive activity.

Definition

An inverse agonist is a ligand that binds a constitutively active receptor and reduces its basal signalling below the level seen in the absence of ligand, reflecting negative efficacy; it is distinguished from a neutral antagonist, which binds with affinity but does not alter constitutive activity.

Scope

This topic covers constitutive (basal) receptor activity, the definition of inverse agonism as negative efficacy, its experimental distinction from neutral antagonism, and its interpretation through two-state and conformational models of receptor activation. It is a methodological reference within pharmacodynamics and does not address drug selection or dosing.

Core questions

• What is constitutive (basal) receptor activity, and how is it measured?
• How does an inverse agonist differ from a neutral antagonist?
• What is meant by 'negative efficacy'?
• Why can a ligand classified as an antagonist behave as an inverse agonist in a constitutively active system?

Key concepts

• Constitutive (basal) activity
• Negative efficacy
• Inverse agonist versus neutral antagonist
• Receptor-state equilibrium (active/inactive)
• Detection requires measurable basal signalling
• Context dependence of antagonist classification

Key theories

Two-state (conformational) receptor model

Treats the receptor as existing in equilibrium between inactive and active states; basal activity reflects spontaneous active-state formation, agonists stabilise the active state, neutral antagonists bind both states equally, and inverse agonists preferentially stabilise the inactive state, lowering basal signalling.

Mechanisms

If a receptor population spontaneously adopts an active conformation in the absence of ligand, it generates a baseline (constitutive) signal. A ligand that preferentially binds and stabilises the inactive conformation shifts the equilibrium away from the active state, reducing signalling below baseline; this is inverse agonism, formally a negative efficacy. A neutral antagonist, by contrast, binds the active and inactive states with equal affinity, so it does not move the equilibrium and leaves basal activity unchanged while still blocking agonists. Costa and Herz demonstrated negative intrinsic activity directly at G-protein-coupled receptors, and conformational models of receptor activation, as reviewed for GPCRs, account for the full continuum from full agonist through neutral antagonist to inverse agonist. Because inverse agonism is defined relative to a basal level, it can only be observed where constitutive activity is appreciable; in systems with little basal activity an inverse agonist and a neutral antagonist are experimentally indistinguishable.

Clinical relevance

The recognition that many ligands previously classed as antagonists are in fact inverse agonists refined the understanding of how receptor-targeting drugs work, particularly where receptors show constitutive activity. This entry is reference material on how inverse agonism is defined and detected; it is not a basis for individual treatment or dosing decisions.

Evidence & guidelines

The definitions of inverse agonist, constitutive activity, and negative efficacy used here follow the IUPHAR recommendations on terms and symbols in quantitative pharmacology.

History

Constitutive receptor activity and inverse agonism were brought to prominence by Costa and Herz's (1989) demonstration of negative intrinsic activity at opioid receptors, followed by work on constitutively active mutant and wild-type G-protein-coupled receptors. These findings overturned the simple agonist-antagonist dichotomy and motivated two-state and multi-state conformational models in which efficacy spans positive, zero, and negative values.

Key figures

• Tommaso Costa
• Albert Herz
• Terry Kenakin
• Brian K. Kobilka
• Richard R. Neubig

Seminal works

• costa-herz-1989
• kobilka-2007
• neubig-2003

Frequently asked questions

How is an inverse agonist different from a regular (neutral) antagonist?

A neutral antagonist blocks agonists without changing the receptor's baseline activity, whereas an inverse agonist lowers that baseline activity below its unliganded level. The difference is only observable when the receptor has constitutive activity.

What does 'negative efficacy' mean?

It means the ligand does not merely fail to activate the receptor but actively reduces its spontaneous (constitutive) signalling, placing it below neutral antagonists on the efficacy scale.